Routine

Glucocorticoid-induced osteoporosis

Steroid-related fracture prevention · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Long-term glucocorticoid therapy causes rapid early bone loss and increases fracture risk out of proportion to bone density, particularly vertebral fractures. Bone protection should be considered at the start of prolonged steroid therapy rather than after a fracture occurs.

Red flags

  • New back pain / height loss (vertebral fracture)
  • Fragility fracture on treatment
  • High-dose or very prolonged steroid exposure
  • Prior osteoporotic fracture
  • Features of myeloma or malignancy

Assessment

Differential diagnosis

  • Postmenopausal / age-related osteoporosis
  • Osteomalacia (vitamin D deficiency)
  • Metastatic bone disease
  • Multiple myeloma
  • Hyperparathyroidism
  • Other secondary osteoporosis

Investigations

  • DEXA bone densitometry (baseline and monitoring)
  • Fracture risk assessment (FRAX with glucocorticoid adjustment)
  • Vertebral imaging if back pain / height loss
  • Serum calcium, phosphate, vitamin D, renal function
  • Coeliac, myeloma and endocrine screen where secondary cause suspected
  • Bone turnover markers in selected cases

Management

  • Assess fracture risk at the outset in anyone starting >=3 months of oral glucocorticoids
  • Use the lowest effective steroid dose and shortest duration; consider steroid-sparing agents
  • Advise weight-bearing exercise, smoking cessation, reduced alcohol and falls prevention
  • Ensure adequate calcium and vitamin D intake/supplementation
  • Start an oral bisphosphonate early in higher-risk patients (older, prior fracture, high dose)
  • Use IV bisphosphonate or denosumab if oral therapy is unsuitable
  • Consider teriparatide for very high risk or recurrent fractures on treatment
  • Reassess risk and bone density periodically and when steroids stop

Drugs & doses

Alendronic acid — 70 mg PO once weekly (first-line bone protection)
Risedronate — 35 mg PO once weekly as alternative
Colecalciferol — 800-2000 units PO OD with calcium 1000 mg daily
Zoledronic acid — 5 mg IV once yearly if oral bisphosphonate unsuitable
Denosumab — 60 mg SC every 6 months
Teriparatide — 20 micrograms SC OD for very high fracture risk

Disposition

Outpatient management integrated with the underlying rheumatological condition; no admission required.

Complications & pitfalls

  • Vertebral and hip fragility fractures
  • Chronic pain and kyphosis
  • Loss of independence after hip fracture
  • Avascular necrosis (separate steroid complication)
  • Rare bisphosphonate adverse effects (atypical fracture, ONJ)

Exam pearls

  • Fracture risk rises within 3-6 months of starting steroids - act early, do not wait for low DEXA
  • Glucocorticoids increase fracture risk at any given bone density, so treat at higher T-scores than in primary osteoporosis
  • Vertebral fractures are often silent - have a low threshold to image
  • Always co-prescribe calcium and vitamin D with bone-protective therapy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.